Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

T Cells Isolated from G-CSF-treated Multiple Myeloma Patients Are Suitable for the Generation of BCMA-directed CAR-T cells

June 28, 2022

[Molecular Therapy-Methods & Clinical Development] Scientists established whether granulocyte colony-stimulating factor treatment (G-CSF) negatively influenced T cell phenotype and to ascertain whether previous exposure of T cells to G-CSF was deleterious for anti-BCMA CAR-T cells.

The Establishment of Polypeptide PSMA-Targeted Chimeric Antigen Receptor-Engineered Natural Killer Cells for Castration-Resistant Prostate Cancer and the Induction of Ferroptosis-Related Cell Death

June 27, 2022

[Cancer Communications] Scientists designed a novel CAR-natural killer cells with a clinically significant tumoricidal effect on castration-resistant prostate cancer.

The Healing of Bone Defects by Cell-Free and Stem Cell-Seeded 3D-Printed PLA Tissue-Engineered Scaffolds

June 27, 2022

[Journal of Orthopaedic Surgery and Research] The authors showed that both cell-free and stem cell-seeded scaffolds exhibited superb healing compared with the empty defect controls, and new bone and connective tissues were formed in the healing site after 8 and 12 weeks, postoperatively.

Astellas’ Gene Therapy Strategy Faces Fresh Setback as FDA Puts Pompe Disease Med on Hold

June 27, 2022

[Fierce Biotech] Astellas’ gene therapy ambitions have faced yet another setback. The FDA has slammed the breaks on a Phase I/II study of the Japanese pharma’s Pompe disease med while the regulator investigates a report of nerve damage in one of the trial’s participants.

Development of STEAP1 Targeting Chimeric Antigen Receptor for Adoptive Cell Therapy against Cancer

June 27, 2022

[Molecular Therapy-Oncolytics] Investigators describe the development of a CAR against the six-transmembrane epithelial antigen of prostate-1 (STEAP1), which is expressed in ∼90% of prostate cancers, and subgroups of other malignancies.

Comparative Efficacy and Mechanism of Action of Cardiac Progenitor Cells after Cardiac Injury

June 27, 2022

[iScience] Transplanted neonatal mesenchymal stem cells significantly increased the number of tissue reparative macrophages and regulatory T cells and decreased monocyte-derived inflammatory macrophages and neutrophils in the host myocardium.

Kinetics of Disappearance and Appearance of Isoagglutinins A and B after ABO-Incompatible Hematopoietic Stem Cell Transplantation

June 27, 2022

[Bone Marrow Transplantation] The authors investigated the time to disappearance and appearance of isoagglutinins after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Effects of Mesenchymal Stem Cell Transplantation on Spinal Cord Injury Patients

June 27, 2022

[Cell and Tissue Research] Investigators review the beneficial effects of mesenchymal stem cell (MSC) transplantation in spinal cord injury clinical studies with a special focus on the MSC properties and limitations of MSC transplantation.

TreeFrog Therapeutics Launches a $100,000 Research Grant in Regenerative Medicine

June 27, 2022

[TreeFrog Therapeutics] TreeFrog Therapeutics announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine.

CRISPR-Mediated MECOM Depletion Retards Tumor Growth by Reducing Cancer Stem Cell Properties in Lung Squamous Cell Carcinoma

June 27, 2022

[Molecular Therapy] Forced expression of MECOM in LUSC cell lines promoted cancer stem cells (CSC) properties, and its knockout inhibited CSC phenotypes.

Intravenously Transplanted Mesenchymal Stromal Cells: A New Endocrine Reservoir for Cardioprotection

June 23, 2022

[Stem Cell Research & Therapy] MSCs were isolated from human placenta tissue, and DF-MSCs or Gluc-MSCs were generated by transduced with firefly luciferase/enhanced green fluorescence protein or Gaussia luciferase lactadherin fusion protein.

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase II Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 23, 2022

[BioRestorative Therapies, Inc.] BioRestorative Therapies, Inc. announced it has reached an agreement with its second clinical site for its Phase II clinical trial targeting chronic lumbar disc disease.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.